Centogene has long been known for its expertise in the field of rare disease genetics – helping over 600,000 patients and building a rare disease-centric Bio/Databank. Aspiring to reduce the heavy burden of rare diseases through data-driven insights, the company has established itself as the leading partner of choice for patients, physicians, and pharma partners.
Leveraging its unparalleled genomics knowledge and rare disease expertise while expanding technology capabilities, Centogene is confident about its path to enabling the cure of 100 rare diseases.
Andrin Oswald, M.D., Chief Executive Officer at Centogene commented: “Over the past 15 years, Centogene has built a unique expertise and has become the leading data-driven insights provider purely focused on rare genetic diseases. We are now embarking on our next growth phase – enabling the cure of 100 rare diseases within the next 10 years. This represents the potential to significantly contribute to reducing the burden of rare diseases.”
At the Virtual Investor Event, Centogene announced its strategic multi-pronged approach to diagnose, understand, and treat global rare diseases by finding, connecting, and investigating patients and their biology.
The link to the article can be found here.